• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by CareDx Inc. (Amendment)

    2/13/24 4:05:40 PM ET
    $CDNA
    Medical Specialities
    Health Care
    Get the next $CDNA alert in real time by email
    SC 13G/A 1 caredx_13ga1.htm SC 13G/A
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 1)*
     
    CareDx, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    14167L103
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)
       

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).  

     
     
    CUSIP No. 14167L103 13G Page 2 of 8

     

                 
    1.

    Names Of Reporting Persons

    Gagnon Securities LLC

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    Delaware Limited Liability Company

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power     0
    6. shared voting power     2,208,268
    7. sole dispositive power     0
    8. shared dispositive power     2,518,484
    9. aggregate amount beneficially owned by each reporting person   2,518,484
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    4.7%

    12. type of reporting person (See Instructions)     IA, BD

     

     
     
     
    CUSIP No. 14167L103 13G Page 3 of 8

     

                 
    1.

    Names Of Reporting Persons

    Gagnon Advisors, LLC

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    Delaware Limited Liability Company

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power     0
    6. shared voting power     554,851
    7. sole dispositive power     0
    8. shared dispositive power    

    554,851

    9. aggregate amount beneficially owned by each reporting person  

    554,851

    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    1.0%

    12. type of reporting person (See Instructions)     IA

     

     
     
     
    CUSIP No. 14167L103 13G Page 4 of 8

     

                 
    1.

    Names Of Reporting Persons

    Neil Gagnon

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    USA

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power    

    169,879

    6. shared voting power    

    2,885,562

    7. sole dispositive power    

    169,879

    8. shared dispositive power    

    3,203,597

    9. aggregate amount beneficially owned by each reporting person  

    3,373,476

    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    6.2%

    12. type of reporting person (See Instructions)     IN

     

     
     
     
    CUSIP No. 14167L103 13G Page 5 of 8
    Item 1.  

     

    (a) Name of Issuer: CareDx, Inc.
         
    (b) Address of Issuer’s Principal

    8000 Marina Blvd, 4th Floor

      Executive Offices:

    Brisbane, California 94005

     

    Item 2.

    (a) Name of Person Filing:

    Neil Gagnon has sole voting and dispositive power over 169,879 shares of the Issuer’s Common Stock, par value $0.001 per share (the “Common Stock”). In addition, Mr. Gagnon has shared voting power over 2,885,562 shares of Common Stock and shared dispositive power over 3,203,597 shares of Common Stock.

     

    Mr. Gagnon is the managing member and principal owner of Gagnon Securities LLC (“GS”), an investment adviser registered with the U.S. Securities and Exchange Commission (“SEC”) under the Investment Advisers Act of 1940, as amended (the “Advisers Act”), and a registered broker-dealer, in its role as investment manager to several customer accounts, foundations, partnerships and trusts (collectively, the “Accounts”) to which it furnishes investment advice. GS and Mr. Gagnon may be deemed to share voting power with respect to 2,208,268 shares of Common Stock held in the Accounts and dispositive power with respect to 2,518,484 shares of Common Stock held in the Accounts. GS and Mr. Gagnon expressly disclaim beneficial ownership of all securities held in the Accounts.

     

    Mr. Gagnon is also the Chief Executive Officer of Gagnon Advisors, LLC (“Gagnon Advisors”), an investment adviser registered with the SEC under the Advisers Act. Mr. Gagnon and Gagnon Advisors, in its role as investment manager to Gagnon Investment Associates, LLC (“GIA”), a private investment fund, may be deemed to share voting and dispositive power with respect to the 554,851 shares of Common Stock held by GIA. Gagnon Advisors and Mr. Gagnon expressly disclaim beneficial ownership of all securities held by GIA.

     

    (b) Address of Principal Business Office 1370 Ave. of the Americas, 26th Floor
      or, if none, Residence: New York, NY 10019

     

    (c) Citizenship:

    Gagnon Securities LLC

    Delaware Limited Liability Company

       

    Gagnon Advisors, LLC

    Delaware Limited Liability Company

       

    Neil Gagnon

    USA

         
    (d) Title of Class of Securities:

    Common Stock, par value $0.001 per share

         
    (e) CUSIP Number: 14167L103

     

     
     
     
    CUSIP No. 14167L103 13G Page 6 of 8
       
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)  o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b)  o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c)  o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d)  o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
         
    (e)  o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f)  o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g)  o A parent holding company or control person in accordance with § 13d-1(b)(1)(ii)(G);
         
    (h)  o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i)  o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j)  o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k)  o Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

     
     
     
    CUSIP No. 14167L103 13G Page 7 of 8
    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:

    Gagnon Securities LLC

    2,518,484

         

    Gagnon Advisors, LLC

    554,851

         

    Neil Gagnon

    3,373,476

           
      (b) Percent of class:

    Gagnon Securities LLC

    4.7%

         

    Gagnon Advisors, LLC

    1.0%

         

    Neil Gagnon

    6.2%

           
         

    Calculation of percentage of beneficial ownership is based on 54,098,378 shares outstanding as of November 6, 2023, as disclosed in the Issuer’s Form 10-Q for the quarter ended September 30, 2023, filed with the SEC on November 8, 2023.

           
      (c) Number of shares as to which the person has:

     

      (i) Sole power to vote or to direct the vote:

    Gagnon Securities LLC

    0

         

    Gagnon Advisors, LLC

    0
         

    Neil Gagnon

    169,879

           
      (ii) Shared power to vote or to direct the vote:

    Gagnon Securities LLC

    2,208,268

         

    Gagnon Advisors, LLC

    554,851

         

    Neil Gagnon

    2,885,562

           
      (iii) Sole power to dispose or to direct the disposition of:

    Gagnon Securities LLC

    0
         

    Gagnon Advisors, LLC

    0
         

    Neil Gagnon

    169,879

           
      (iv) Shared power to dispose or to direct the disposition of:

    Gagnon Securities LLC

    2,518,484

         

    Gagnon Advisors, LLC

    554,851

         

    Neil Gagnon

    3,203,597

     

    Item 5. Ownership of Five Percent or Less of a Class.
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    The Accounts described above in Item 2 have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, securities held in their respective accounts. To the knowledge of the Reporting Persons the interest in any such account does not exceed 5% of the class of securities. Except to the extent described herein, the Reporting Person disclaims beneficial ownership of all such securities.

     

    Items 7 – 9. Not Applicable.

     

     
     
     
    CUSIP No. 14167L103 13G Page 8 of 8
       
    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 230.14a-11.

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 13, 2024

       
      NEIL GAGNON
     
     

    /s/ Neil Gagnon

       
     

    GAGNON SECURITIES LLC

       
     

    /s/ Neil Gagnon

      Name:  Neil Gagnon 
     

    Title:    Managing Member

       
     

    GAGNON ADVISORS, LLC

       
     

    /s/ Neil Gagnon

      Name:  Neil Gagnon 
     

    Title:    Chief Executive Officer

       
     
     
    Get the next $CDNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDNA

    DatePrice TargetRatingAnalyst
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    8/28/2024$28.00Underweight
    Wells Fargo
    8/19/2024$40.00Neutral → Buy
    BTIG Research
    5/13/2024Outperform → Mkt Perform
    Raymond James
    5/1/2024$15.00Hold → Buy
    Craig Hallum
    11/9/2023$10.00Equal-Weight → Overweight
    Stephens
    8/15/2023$12.00Mkt Perform → Outperform
    Raymond James
    5/11/2023Buy → Neutral
    BTIG Research
    More analyst ratings

    $CDNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CareDx Announces Repurchase of 5% of Outstanding Shares

      Board of Directors Authorizes New $50 Million Share Repurchase Program CareDx, Inc. (NASDAQ:CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the repurchase of $50 million of its common stock representing approximately 5% of outstanding shares. The share repurchase follows the completion of the company's seventh consecutive quarter of testing services volume growth and a first-quarter total revenue of $84.7 million, representing 18% year-over-year growth. CareDx ended

      6/3/25 4:30:00 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports First Quarter 2025 Results

      First Quarter Revenue of $84.7 Million, Increased 18% Year-Over-Year Grew Testing Services Volume to Approximately 47,100, Marking Seventh Consecutive Quarter of Sequential Testing Services Volume Growth CareDx, Inc. (NASDAQ:CDNA) today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Reported first quarter revenue of $84.7 million, increased 18% year-over-year Testing services revenue of $61.9 million, increased 15% year-over-year, and testing services volume of approximately 47,100, increased 12% year-over-year GAAP net loss of $10.4 million, non-GAAP net income of $5.4 million, and positive adjusted EBITDA of $4.6 million,

      4/30/25 4:05:00 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ ("CareDx" or the "Company")— a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 7, 2025, CareDx granted to Jennifer Foley, the Company's newly appointed Chief Product Officer, certain stock awards as an inducement material to Ms. Foley's employment with CareDx. CareDx granted Ms. Foley 36,231 restricted stock units ("RSUs") pursuant to the Company's 2016 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Company's Board o

      4/21/25 4:01:00 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    SEC Filings

    See more
    • CareDx Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CareDx, Inc. (0001217234) (Filer)

      6/12/25 4:32:37 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • SEC Form 144 filed by CareDx Inc.

      144 - CareDx, Inc. (0001217234) (Subject)

      6/11/25 4:20:36 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - CareDx, Inc. (0001217234) (Filer)

      6/3/25 4:30:13 PM ET
      $CDNA
      Medical Specialities
      Health Care